Invention Grant
- Patent Title: IL-17A binding agent and uses thereof
-
Application No.: US15035550Application Date: 2014-10-27
-
Publication No.: US09862765B2Publication Date: 2018-01-09
- Inventor: Lianshan Zhang , Jiajian Liu , Guoqing Cao , Piaoyang Sun
- Applicant: Shanghai Hengrui Pharmaceutical Co., Ltd. , Jiangsu Hengrui Medicine Co., Ltd.
- Applicant Address: CN Shanghai CN Lianyungan, Jiangsu
- Assignee: Shanghai Hengrui Pharmaceutical Co., Ltd.,Jiangsu Hengrui Medicine Co., Ltd.
- Current Assignee: Shanghai Hengrui Pharmaceutical Co., Ltd.,Jiangsu Hengrui Medicine Co., Ltd.
- Current Assignee Address: CN Shanghai CN Lianyungan, Jiangsu
- Agency: Panitch Schwarze Belisario & Nadel LLP
- Priority: CN201310580942 20131118
- International Application: PCT/CN2014/089542 WO 20141027
- International Announcement: WO2015/070697 WO 20150521
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C12N15/63 ; C07K16/24 ; C07K14/54 ; A61K39/00
Abstract:
Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
Public/Granted literature
- US20160289321A1 IL-17A BINDING AGENT AND USES THEREOF Public/Granted day:2016-10-06
Information query
